Impact of prescription patterns of antithrombotic treatment on atrial fibrillation-related ischemic stroke

References

• Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492.
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lindgren A, et al. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke. 2014;45(9):2599–2605.
   PubMed Web of Science ®Google Scholar
• Cerasuolo JO, Montero-Odasso M, Ibañez A, et al. Decision-making interventions to stop the global atrial fibrillation-related stroke tsunami. Int J Stroke. 2017;12(3):222–228.
   PubMed Web of Science ®Google Scholar
• Masjuán J, Álvarez-Sabín J, Blanco M, et al. Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack. Rev Neurol. 2014;59(1):25–36.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104–132.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A, et al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care. Rev Esp Cardiol (Engl Ed). 2014;67(2):150–151.
   PubMed Web of Science ®Google Scholar
• Vallakati A, Lewis WR. Underuse of anticoagulation in patients with atrial fibrillation. Postgrad Med. 2016;128(2):191–200.
   PubMed Web of Science ®Google Scholar
• O'Brien EC, Simon DN, Allen LA, et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014;168(4):487–494.
   PubMed Web of Science ®Google Scholar
• Bertozzo G, Zoppellaro G, Granziera S, et al. Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation. J Thromb Haemost. 2016;14(11):2124–2131.
   PubMed Web of Science ®Google Scholar
• Escobar C, Barrios V, Prieto L. Therapeutic behavior of primary care physicians in patients with atrial fibrillation taking vitamin K antagonists not adequately controlled. Eur J Intern Med. 2016;30:e17–e18.
   PubMed Web of Science ®Google Scholar
• Björck F, Ek A, Johansson L, et al. Warfarin persistence among atrial fibrillation patients - why is treatment ended? Cardiovasc Ther. 2016;34(6):468–474.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154–162.
   PubMed Web of Science ®Google Scholar
• Cowan JC, Wu J, Hall M, et al. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018;39(32):2975–2983.
   PubMed Web of Science ®Google Scholar
• Chamberlain AM, Brown RD, Alonso A, et al. No decline in the risk of stroke following incident atrial fibrillation since 2000 in the community: a concerning trend. J Am Heart Assoc. 2016;5(6):e003408.
   PubMed Web of Science ®Google Scholar
• Yiin GSC, Howard DPJ, Paul NLM, et al. Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study. J Neurol Neurosurg Psychiatry. 2017;88(1):12–18.
   PubMed Web of Science ®Google Scholar
• Freixa-Pamias R, Gràcia PB, Rodríguez Latre ML, et al. Impact of an integral assistance model between primary care and cardiology on the management of patients with ischemic heart disease or atrial fibrillation. J Comp Eff Res. 2019;8(2):103–111.
   PubMed Web of Science ®Google Scholar
• Freixa-Pamias R, Blanch Gràcia P, Rodríguez Latre ML, et al. Improving medical attention through an integral care model for patients with ischemic heart disease or atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2019;72(9):779–781.
   PubMed Web of Science ®Google Scholar
• Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14.
   PubMed Web of Science ®Google Scholar
• Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010;60(572):e128–e136.
   PubMed Web of Science ®Google Scholar
• Positioning therapeutic report UT_ACOD/V5/21112016. Criteria and general recommendations for the use of direct oral anticoagulants for the prevention of stroke and systemic embolism among patients with nonvalvular atrial fibrillation. [Last access 2020 Oct 28]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/criterios-anticoagulantes-orales.pdf.
   Google Scholar
• Barrios V, Calderón A, Escobar C, et al. Patients with atrial fibrillation in a primary care setting: val-FAAP study. Rev Esp Cardiol (Engl Ed). 2012;65(1):47–53.
   PubMed Web of Science ®Google Scholar
• Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847.
   PubMed Web of Science ®Google Scholar
• Buchwald F, Norrving B, Petersson J. Atrial fibrillation in transient ischemic attack versus ischemic stroke: a Swedish Stroke Register (Riksstroke) Study. Stroke. 2016;47(10):2456–2461.
   PubMed Web of Science ®Google Scholar
• Yang Q, Churilov L, Fan D, et al. 1.4 times increase in atrial fibrillation-related ischemic stroke and TIA over 12 years in a stroke center. J Neurol Sci. 2017;379:1–6.
   PubMed Web of Science ®Google Scholar
• Martinez C, Katholing A, Wallenhorst C, et al. Increasing incidence of non-valvular atrial fibrillation in the UK from 2001 to 2013. Heart. 2015;101(21):1748–1754.
   PubMed Web of Science ®Google Scholar
• Halcox JPJ, Wareham K, Cardew A, et al. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. Circulation. 2017;136(19):1784–1794.
   PubMed Web of Science ®Google Scholar
• Shantsila E, Wolff A, Lip GY, et al. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. Br J Gen Pract. 2015;65(630):e16–e23.
   PubMed Web of Science ®Google Scholar
• Holt TA, Hunter TD, Gunnarsson C, et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract. 2012;62(603):e710–e717.
   PubMed Web of Science ®Google Scholar
• Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart. 2013;99(16):1166–1172.
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–645.
   PubMed Web of Science ®Google Scholar
• Sheth H, McNally D, Santibanez-Koref M, et al. Association of stroke and bleed events in non-valvular atrial fibrillation patients with direct oral anticoagulant prescriptions in NHS England between 2013 and 2016. PLoS One. 2019;14(6):e0218878.
   PubMed Web of Science ®Google Scholar
• Vinereanu D, Lopes RD, Bahit MC, et al. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet. 2017;390(10104):1737–1746.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Pinto FJ, Hankey GJ, et al. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace. 2015;17(7):1007–1017.
   PubMed Web of Science ®Google Scholar
• Escobar C, Martí-Almor J, Pérez Cabeza A, et al. Direct oral anticoagulants versus vitamin K antagonists in real-life patients with atrial fibrillation. A systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed). 2019;72(4):305–316.
   PubMed Web of Science ®Google Scholar
• Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost. 2016;115(01):31–39.
   PubMed Web of Science ®Google Scholar
• Sato T, Aizawa Y, Fuse K, et al. The comparison of inappropriate-low-doses use among 4 direct oral anticoagulants in patients with atrial fibrillation: from the database of a single-center registry. J Stroke Cerebrovasc Dis. 2018;27(11):3280–3288.
   PubMed Web of Science ®Google Scholar
• Pancholy SB, Sharma PS, Pancholy DS, et al. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol. 2014;113(3):485–490.
   PubMed Web of Science ®Google Scholar
• Raccah BH, Perlman A, Zwas DR, et al. Gender differences in efficacy and safety of direct oral anticoagulants in atrial fibrillation: systematic review and network meta-analysis. Ann Pharmacother. 2018;52(11):1135–1142.
   PubMed Web of Science ®Google Scholar
• Shroff GR, Solid CA, Herzog CA. Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: a 15-year perspective (1992–2007). JAMA Intern Med. 2013;173(2):159–160.
   PubMed Web of Science ®Google Scholar
• Yu AYX, Malo S, Svenson LW, et al. Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for nonvalvular atrial fibrillation: a Canadian population-based study. J Am Heart Assoc. 2017;6(11):e007129.
   PubMed Web of Science ®Google Scholar
• Soo Y, Chan N, Leung KT, et al. Leung. Age-specific trends of atrial fibrillation-related ischaemic stroke and transient ischaemic attack, anticoagulant use and risk factor profile in Chinese population: a 15-year study. J Neurol Neurosurg Psychiatry. 2017;88(9):744–748.
   PubMed Web of Science ®Google Scholar
• Katz DF, Maddox TM, Turakhia M, et al. Contemporary trends in oral anticoagulant prescription in atrial fibrillation patients at low to moderate risk of stroke after guideline-recommended change in use of the CHADS2 to the CHA2DS2-VASc score for thromboembolic risk assessment: analysis from the national cardiovascular data registry's outpatient practice innovation and clinical excellence atrial fibrillation registry. Circ Cardiovasc Qual Outcomes. 2017;10(5):e003476.
   Web of Science ®Google Scholar
• Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE registry. JAMA Cardiol. 2016;1(1):55–62.
   PubMed Web of Science ®Google Scholar
• Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open. 2014;4(6):e004301.
   PubMed Web of Science ®Google Scholar
• van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441–2448.
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FD, Fletcher K, et al. BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Welner SA, Cowell W, et al. Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. Thromb Haemost. 2011;106(1):34–44.
   PubMed Web of Science ®Google Scholar
• Gragnano F, Calabrò P, Valgimigli M. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J. 2019;40(2):216–217.
   PubMed Web of Science ®Google Scholar
• Ueki Y, Bär S, Losdat S, et al. Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention. 2020;16(5):371–379.
   PubMed Web of Science ®Google Scholar
• Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899–906.
   PubMed Web of Science ®Google Scholar
• Wolff A, Shantsila E, Lip GY, et al. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. Age Ageing. 2015;44(5):874–878.
   PubMed Web of Science ®Google Scholar